🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💥Last week to submit your abstract to #IUCS25, you could showcase your research in the field of urological cancers! 🧑‍🏫Accepted Abstracts will be e-posters shown onsite & mini-oral 📆June 30th, 2025 Info & Abstract submssion 👉ow.ly/ipV450W3otF #urology #cancer

🎙️ "We’ve come a long way. Patients in Romania now can access the same treatments as Western Europe." – Dr. Maria Barbu at #IUCS2024 From ADT to abiraterone and olaparib, hear how prostate cancer care is evolving in Eastern Europe. 📺 Watch now: youtu.be/H5mCmUzb_N4 🌐

Where does #radiotherapy (SABR) sit alongside systemic therapies in #renalcancer? Join us & discuss with John McGrane from Sunrise Oncology Centre, Royal Cornwall Hospitals NHS Trust in presence or virtually! Discover more and register for free 🧷ow.ly/EBl850VSvQw #Oncology #IUCS25 #urology

🌟#IUCS25 Poll – Oligoprogression in mRCC 👴 70 y/o man with good-risk mRCC, on 1L pazopanib for 3 years 🟢 Excellent response overall, well tolerated 🆙 Now with isolated progression in 2 mediastinal nodes (1–1.5 cm) 💬 What’s your next step?

Renal cancer biomakers Javier Molina Cerrillo #GUARDSymposium2025. Progress at last with KIM1 (prognostic & potentially predictive for IO). Are prospective trials needed? How and when do we define high? Are different response cutpoints needed for different treatments? OncoAlert

Metastatic CSPC is changing and becoming personalised. The AMPLITUDE trial #GUARDSymposium2025 by AttardLab supporting PARPi in HRR/BRCA altered disease. PTEN and PSMA may also have a role for chemo and radioligands. A new era in prostate cancer OncoAlert

📣Abstract Submission Deadline for #IUCS25 has been postponed! 📆July 10, 2025 🧑‍🏫Accepted Abstracts will be e-posters shown onsite & mini-oral to showcase your research in the field of urological cancers! Info & Abstract submssion👉ow.ly/ipV450W3otF #urology #cancer

International Urology Cancer Summit – The Abstract Submission Deadline for IUCS25 has been Postponed! International Urology Cancer Summit oncodaily.com/blog/internati… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #IUCS25

Not all rising PSAs are equal. A population study of 17,753 men redefines high-risk biochemical recurrence (HR-BCR) after prostate cancer treatment. Half of men with PSA rise don’t need treatment intensification. Time, doubling rate, and risk matter more than one number.

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…

💫🌟🚨 SUNNIFORECAST Trial — Published in Annals of Oncology 🎯 First randomized phase II trial in nccRCC: Ipi/Nivo vs. SOC OncoAlert Annals of Oncology 🟠 12-mo OS: 78% vs. 68% (HR 0.81, p=0.026) 🟠 Median OS: 33.2 vs. 25.2 months 🟠 ORR: 33% vs. 20% (CR: 8% vs. 2%) 🟠 CPS ≥1

🌟🎓✔️🖋MUST READ Key Updates in Testicular Cancer: Optimizing Survivorship and Survival 👨‍⚕️ Authors: Dr. Lawrence Einhorn DrBagrodia Ragnhild Hellesnes Lucia Nappi Sia Daneshmand, M.D. University of British Columbia  Testicular Cancer Society IU School of Medicine Indiana University Department of Urology  IU Simon Comprehensive Cancer Center OncoAlert 🔹 Testicular cancer: high

🎙️Out today🚨 🎙️New Simply Oncology episode on Renal SABR in #renalcancer with Harshani Green 💙 @harshanigreen.bsky.social 🎙️We look at the exciting role that radiotherapy may have as a potential alternative to surgery - in select cases. Oncology News Today International Urology Cancer Summit Kidney Cancer News

📢The submission to a joint special collection of original papers on #urological cancers of Sage Clinical Med Insights: Oncology and Therapeutic Advances in Urology supported by #IUCS25 is now open! 🗓️Deadline March 31, 2026. Info 👉 ow.ly/ST0K50WnuOM Giuseppe Banna Ravindran Kanesvaran #urology #cancer

#IUCS25 Poll IO/TKI in mRCC: Is It Time for a Break? OncoAlert 👨‍⚕️ 66-year-old man with metastatic RCC 💊 1L PEMBRO + AXI 🕒 On treatment for 18 months ✅ Sustained PR, well tolerated, clinically stable 🗣️ “Do I need to stay on both drugs forever?” 💬 What’s your approach?

🌟Therapeutic Targeting of MMR-Deficient Cancers🌟 🖋️ Paul Johannet, Benoit Rousseau, Carol Aghajanian, Mike Foote Memorial Sloan Kettering Cancer Center Luis Diaz Nature Reviews Cancer nature OncoAlert “MMRd tumors: an immunogenic paradox — vulnerable yet resilient” 🔵 Immune-checkpoint inhibitors

Just came online in The Lancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh Prostate Cancer Foundation UroToday.com OncoAlert

We’re proud to present the KidneyCAN Catalyst Award to Dr. Rana McKay of UC San Diego. Dr. McKay is a leader whose work has helped move the field of kidney cancer forward through groundbreaking research, clinical collaboration, and a deep commitment to patients and advocacy. Her

☄️ Discover the #IUCS25 programme! Learn about the latest in urological cancer therapies from top international speakers and join expert-led discussions. Attend free online or in-person! Learn more and register now! ⤵️ bit.ly/46TvUao International Urology Cancer Summit